Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases

Vedolizumab, a monoclonal antibody directed against integrin α4β7, is an effective treatment for inflammatory bowel diseases. However, a significant number of patients do not achieve steroid-free clinical remission in the first year of treatment. An early identification of these patients is one of t...

Full description

Bibliographic Details
Main Authors: Lorenzo Bertani, Gian Paolo Caviglia, Luca Antonioli, Rinaldo Pellicano, Sharmila Fagoonee, Marco Astegiano, Giorgio Maria Saracco, Elisabetta Bugianesi, Corrado Blandizzi, Francesco Costa, Davide Giuseppe Ribaldone
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Journal of Clinical Medicine
Subjects:
clinical
Crohn’s disease
cytokines
serum
ulcerative colitis
Online Access:https://www.mdpi.com/2077-0383/9/5/1323

Internet

https://www.mdpi.com/2077-0383/9/5/1323

Similar Items